{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:22:41Z","timestamp":1795148561654,"version":"4.10.3"},"reference-count":59,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Complement activation in the diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) results in cytolysis and fatal thrombotic events, which are largely refractory to anticoagulation and\/or antiplatelet therapy. Anticomplement therapy, however, efficiently prevents thrombotic events in PNH and aHUS, but the underlying mechanisms remain unresolved. We show that complement-mediated hemolysis in whole blood induces platelet activation similarly to activation by adenosine 5\u2032-diphosphate (ADP). Blockage of C3 or C5 abolished platelet activation. We found that human platelets failed to respond functionally to the anaphylatoxins C3a and C5a. Instead, complement activation did lead to prothrombotic cell activation in the whole blood when membrane attack complex (MAC)-mediated cytolysis occurred. Consequently, we demonstrate that ADP receptor antagonists efficiently inhibited platelet activation, although full complement activation, which causes hemolysis, occurred. By using an established model of mismatched erythrocyte transfusions in rats, we crossvalidated these findings in\u00a0vivo using the complement inhibitor OmCI and cobra venom factor. Consumptive complement activation in this animal model only led to a thrombotic phenotype when MAC-mediated cytolysis occurred. In conclusion, complement activation only induces substantial prothrombotic cell activation if terminal pathway activation culminates in MAC-mediated release of intracellular ADP. These results explain why anticomplement therapy efficiently prevents thromboembolisms without interfering negatively with hemostasis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010817","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T14:28:12Z","timestamp":1688999292000},"page":"6367-6380","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Complement and platelets: prothrombotic cell activation requires membrane attack complex\u2013induced release of danger signals"],"prefix":"10.1182","volume":"7","author":[{"given":"Marco","family":"Mannes","sequence":"first","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Pechtl","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hafner","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dopler","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Eriksson","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-7372","authenticated-orcid":false,"given":"Vivek Anand","family":"Manivel","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-812X","authenticated-orcid":false,"given":"Lisa","family":"Wohlgemuth","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-038X","authenticated-orcid":false,"given":"David Alexander Christian","family":"Messerer","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6659","authenticated-orcid":false,"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"4Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, University Hospital of Ulm and German Red Cross Blood Service Baden-W\u00fcrttemberg\u2013Hessen, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina N.","family":"Ekdahl","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-2730","authenticated-orcid":false,"given":"Bo","family":"Nilsson","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and Adolescent Medicine, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-1690","authenticated-orcid":false,"given":"Manfred","family":"Hoenig","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and Adolescent Medicine, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Huber-Lang","sequence":"additional","affiliation":[{"name":"1Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-3251","authenticated-orcid":false,"given":"Christian K.","family":"Braun","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and Adolescent Medicine, University Hospital of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany"},{"name":"6Institute of Pharmacy, Biochemical Pharmacy Group, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"issue":"6","key":"2023102415205485800_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2011.08690.x","article-title":"Management of paroxysmal nocturnal haemoglobinuria: a personal view","volume":"153","author":"Luzzatto","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"2023102415205485800_bib2","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023102415205485800_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2007.01.046","article-title":"The pathophysiology of paroxysmal nocturnal hemoglobinuria","volume":"35","author":"Parker","year":"2007","journal-title":"Exp Hematol"},{"issue":"25","key":"2023102415205485800_bib4","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2023102415205485800_bib5","first-page":"1379","article-title":"Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients","volume":"252","author":"Audebert","year":"2005","journal-title":"J\u00a0Neurol"},{"key":"2023102415205485800_bib6","doi-asserted-by":"crossref","first-page":"bcr2015213603","DOI":"10.1136\/bcr-2015-213603","article-title":"Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria","volume":"2016","author":"Azevedo","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"12","key":"2023102415205485800_bib7","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2023102415205485800_bib8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023102415205485800_bib9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"13","key":"2023102415205485800_bib10","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2020007206","article-title":"Complement and the prothrombotic state","volume":"139","author":"Schmidt","year":"2022","journal-title":"Blood"},{"key":"2023102415205485800_bib11","doi-asserted-by":"crossref","first-page":"100834","DOI":"10.1016\/j.blre.2021.100834","article-title":"It takes two to thrombosis: hemolysis and complement","volume":"50","author":"Delvasto-Nu\u00f1ez","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"2023102415205485800_bib12","first-page":"9","article-title":"Catastrophic antiphospholipid syndrome: a clinical review","volume":"3","author":"Nayer","year":"2014","journal-title":"J\u00a0Nephropathol"},{"key":"2023102415205485800_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2017.06.014","article-title":"A\u00a0novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome","volume":"156","author":"Rand","year":"2017","journal-title":"Thromb Res"},{"issue":"4","key":"2023102415205485800_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023102415205485800_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2023102415205485800_bib16","doi-asserted-by":"crossref","first-page":"e0207218","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PLoS One"},{"issue":"19","key":"2023102415205485800_bib17","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023102415205485800_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","article-title":"Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry","volume":"97","author":"Lee","year":"2013","journal-title":"Int J Hematol"},{"issue":"2","key":"2023102415205485800_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5045\/kjh.2011.46.2.111","article-title":"Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases","volume":"46","author":"Baek","year":"2011","journal-title":"Korean J Hematol"},{"issue":"4","key":"2023102415205485800_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023102415205485800_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2008.657","article-title":"Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway","volume":"75","author":"Sethi","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"2023102415205485800_bib22","first-page":"459","article-title":"Characterization of C3 in C3 glomerulopathy","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"2023102415205485800_bib23","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2023102415205485800_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2023102415205485800_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jth.13964","article-title":"Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice","volume":"16","author":"Morser","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2023102415205485800_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jth.13999","article-title":"Basic weapons to degrade C3a and C5a","volume":"16","author":"Foley","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"2023102415205485800_bib27","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2017-10-811943","article-title":"Complement and coagulation: so close, yet so far","volume":"130","author":"Schmidt","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2023102415205485800_bib28","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/bph.15245","article-title":"Complement in trauma\u2014traumatised complement?","volume":"178","author":"Huber-Lang","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2023102415205485800_bib29","doi-asserted-by":"crossref","first-page":"918775","DOI":"10.3389\/fimmu.2022.918775","article-title":"Coagulation and complement: key innate defense participants in a seamless web","volume":"13","author":"Pryzdial","year":"2022","journal-title":"Front Immunol"},{"key":"2023102415205485800_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"2023102415205485800_bib31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023102415205485800_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023102415205485800_bib33","doi-asserted-by":"crossref","first-page":"e1800485","DOI":"10.1002\/mabi.201800485","article-title":"Validation of an MPC polymer coating to attenuate surface-induced crosstalk between the complement and coagulation systems in whole blood in in\u00a0vitro and in\u00a0vivo models","volume":"19","author":"Asif","year":"2019","journal-title":"Macromol Biosci"},{"issue":"8","key":"2023102415205485800_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.tips.2022.01.004","article-title":"Compstatins: the dawn of clinical C3-targeted complement inhibition","volume":"43","author":"Lamers","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"2023102415205485800_bib35","doi-asserted-by":"crossref","first-page":"825892","DOI":"10.3389\/fimmu.2022.825892","article-title":"Platelets as key factors in inflammation: focus on CD40L\/CD40","volume":"13","author":"Cognasse","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"2023102415205485800_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet \u03b1-granules: basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev"},{"issue":"16","key":"2023102415205485800_bib37","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.118.034600","article-title":"Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis","volume":"138","author":"Sauter","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"2023102415205485800_bib38","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1038\/s41467-021-23499-w","article-title":"The C5a\/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets","volume":"12","author":"Nording","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2023102415205485800_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0014-2999(01)00733-6","article-title":"Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist","volume":"412","author":"Baurand","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2023102415205485800_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CRD.0000000000000142","article-title":"Cangrelor: a new route for P2Y12 inhibition","volume":"25","author":"Sible","year":"2017","journal-title":"Cardiol Rev"},{"issue":"11","key":"2023102415205485800_bib41","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/trf.12695","article-title":"Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis","volume":"54","author":"Shah","year":"2014","journal-title":"Transfusion (Paris)"},{"issue":"8","key":"2023102415205485800_bib42","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/trf.13674","article-title":"Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats","volume":"56","author":"Kumar","year":"2016","journal-title":"Transfusion (Paris)"},{"issue":"5","key":"2023102415205485800_bib43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"2023102415205485800_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0171-2985(11)80526-7","article-title":"Characterization of the C5a receptor on guinea pig platelets","volume":"183","author":"Kretzschmar","year":"1991","journal-title":"Immunobiology"},{"issue":"1","key":"2023102415205485800_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1432-1033.1992.tb17407.x","article-title":"Synthetic peptides as antagonists of the anaphylatoxin C3a","volume":"210","author":"Kretzschmar","year":"1992","journal-title":"Eur J Biochem"},{"issue":"14","key":"2023102415205485800_bib46","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1182\/blood-2011-03-339705","article-title":"Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes","volume":"118","author":"Rowley","year":"2011","journal-title":"Blood"},{"key":"2023102415205485800_bib47","doi-asserted-by":"crossref","first-page":"1020712","DOI":"10.3389\/fimmu.2022.1020712","article-title":"Complement C3b contributes to Escherichia coli-induced platelet aggregation in human whole blood","volume":"13","author":"Landsem","year":"2022","journal-title":"Front Immunol"},{"key":"2023102415205485800_bib48","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front Immunol"},{"key":"2023102415205485800_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-94-007-6410-1_4","volume-title":"Snake Venoms. Springer","author":"Vogel","year":"2017"},{"issue":"6","key":"2023102415205485800_bib50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1084\/jem.147.6.1713","article-title":"The human complement system in thrombin-mediated platelet function","volume":"147","author":"Polley","year":"1978","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2023102415205485800_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.158.2.603","article-title":"Human platelet activation by C3a and C3a des-arg","volume":"158","author":"Polley","year":"1983","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2023102415205485800_bib52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood.V68.4.875.875","article-title":"Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase","volume":"68","author":"Wiedmer","year":"1986","journal-title":"Blood"},{"issue":"4","key":"2023102415205485800_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V82.4.1192.1192","article-title":"Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria","volume":"82","author":"Wiedmer","year":"1993","journal-title":"Blood"},{"issue":"34","key":"2023102415205485800_bib54","doi-asserted-by":"crossref","first-page":"18205","DOI":"10.1016\/S0021-9258(19)81346-7","article-title":"Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity","volume":"263","author":"Sims","year":"1988","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2023102415205485800_bib55","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.3324\/haematol.2018.198846","article-title":"Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"104","author":"Griffin","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2023102415205485800_bib56","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2015.132183","article-title":"Hemoglobin interaction with GP1b induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis","volume":"100","author":"Singhal","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"2023102415205485800_bib57","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/jth.12422","article-title":"Mechanisms of hemolysis-associated platelet activation","volume":"11","author":"Helms","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023102415205485800_bib58","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2023102415205485800_bib59","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6367\/2085240\/blooda_adv-2023-010817-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6367\/2085240\/blooda_adv-2023-010817-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:50:19Z","timestamp":1698148219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6367\/496801\/Complement-and-platelets-prothrombotic-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":59,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010817","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}